Personalizing breast cancer staging by the inclusion of ER, PR, and HER2

Sanjay P. Bagaria, Partha S. Ray, Myung Shin Sim, Xing Ye, Jaime M. Shamonki, Xiaojiang Cui, Armando E. Giuliano

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

IMPORTANCE: Nonanatomic factors, such as histologic grade and biomarkers, can guide breast cancer management but are not included in the current TNM staging system. OBJECTIVE: To use as an example the triple-negative phenotype (TNP) defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) to examine whether such inclusion improves the prognostic accuracy of TNM staging for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Women diagnosed with primary invasive ductal breast cancer from January 1, 1991, through December 31, 2008, were identified from a prospective institutional database. Excluded were patients who received neoadjuvant therapy, those whose staging information was incomplete, or those whose tumor lacked ER, PR, and HER2 data. Breast cancers were categorized by TNM stage and by the presence or absence of TNP. MAIN OUTCOMES AND MEASURES: Overall survival at 5 years. RESULTS: Database review identified 1842 consecutive eligible patients with breast cancer. When patients were stratified by TNM stage, overall survival curves for those with TNP breast cancer matched those for patients whose non-TNP breast cancer was 1 TNM stage higher. Multivariable analysis showed that TNP status was a powerful prognostic variable, and the likelihood ratio test revealed that the prognostic accuracy of the TNM staging system that incorporated TNP was superior to the current TNM staging system (P < .001). A TNM staging system that incorporated TNP reduced early-stage compression by 15%. CONCLUSIONS AND RELEVANCE: The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging.

Original languageEnglish (US)
Pages (from-to)125-129
Number of pages5
JournalJAMA Surgery
Volume149
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

Neoplasm Staging
Progesterone Receptors
Epidermal Growth Factor
Estrogen Receptors
Breast Neoplasms
Phenotype
Databases
Triple Negative Breast Neoplasms
Neoadjuvant Therapy
Survival
Biomarkers
Outcome Assessment (Health Care)
Neoplasms

ASJC Scopus subject areas

  • Surgery

Cite this

Bagaria, S. P., Ray, P. S., Sim, M. S., Ye, X., Shamonki, J. M., Cui, X., & Giuliano, A. E. (2014). Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surgery, 149(2), 125-129. https://doi.org/10.1001/jamasurg.2013.3181

Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. / Bagaria, Sanjay P.; Ray, Partha S.; Sim, Myung Shin; Ye, Xing; Shamonki, Jaime M.; Cui, Xiaojiang; Giuliano, Armando E.

In: JAMA Surgery, Vol. 149, No. 2, 02.2014, p. 125-129.

Research output: Contribution to journalArticle

Bagaria, SP, Ray, PS, Sim, MS, Ye, X, Shamonki, JM, Cui, X & Giuliano, AE 2014, 'Personalizing breast cancer staging by the inclusion of ER, PR, and HER2', JAMA Surgery, vol. 149, no. 2, pp. 125-129. https://doi.org/10.1001/jamasurg.2013.3181
Bagaria SP, Ray PS, Sim MS, Ye X, Shamonki JM, Cui X et al. Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. JAMA Surgery. 2014 Feb;149(2):125-129. https://doi.org/10.1001/jamasurg.2013.3181
Bagaria, Sanjay P. ; Ray, Partha S. ; Sim, Myung Shin ; Ye, Xing ; Shamonki, Jaime M. ; Cui, Xiaojiang ; Giuliano, Armando E. / Personalizing breast cancer staging by the inclusion of ER, PR, and HER2. In: JAMA Surgery. 2014 ; Vol. 149, No. 2. pp. 125-129.
@article{d74739a3153f4a538ee5850c856e0f3c,
title = "Personalizing breast cancer staging by the inclusion of ER, PR, and HER2",
abstract = "IMPORTANCE: Nonanatomic factors, such as histologic grade and biomarkers, can guide breast cancer management but are not included in the current TNM staging system. OBJECTIVE: To use as an example the triple-negative phenotype (TNP) defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) to examine whether such inclusion improves the prognostic accuracy of TNM staging for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Women diagnosed with primary invasive ductal breast cancer from January 1, 1991, through December 31, 2008, were identified from a prospective institutional database. Excluded were patients who received neoadjuvant therapy, those whose staging information was incomplete, or those whose tumor lacked ER, PR, and HER2 data. Breast cancers were categorized by TNM stage and by the presence or absence of TNP. MAIN OUTCOMES AND MEASURES: Overall survival at 5 years. RESULTS: Database review identified 1842 consecutive eligible patients with breast cancer. When patients were stratified by TNM stage, overall survival curves for those with TNP breast cancer matched those for patients whose non-TNP breast cancer was 1 TNM stage higher. Multivariable analysis showed that TNP status was a powerful prognostic variable, and the likelihood ratio test revealed that the prognostic accuracy of the TNM staging system that incorporated TNP was superior to the current TNM staging system (P < .001). A TNM staging system that incorporated TNP reduced early-stage compression by 15{\%}. CONCLUSIONS AND RELEVANCE: The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging.",
author = "Bagaria, {Sanjay P.} and Ray, {Partha S.} and Sim, {Myung Shin} and Xing Ye and Shamonki, {Jaime M.} and Xiaojiang Cui and Giuliano, {Armando E.}",
year = "2014",
month = "2",
doi = "10.1001/jamasurg.2013.3181",
language = "English (US)",
volume = "149",
pages = "125--129",
journal = "JAMA Surgery",
issn = "2168-6254",
publisher = "American Medical Association",
number = "2",

}

TY - JOUR

T1 - Personalizing breast cancer staging by the inclusion of ER, PR, and HER2

AU - Bagaria, Sanjay P.

AU - Ray, Partha S.

AU - Sim, Myung Shin

AU - Ye, Xing

AU - Shamonki, Jaime M.

AU - Cui, Xiaojiang

AU - Giuliano, Armando E.

PY - 2014/2

Y1 - 2014/2

N2 - IMPORTANCE: Nonanatomic factors, such as histologic grade and biomarkers, can guide breast cancer management but are not included in the current TNM staging system. OBJECTIVE: To use as an example the triple-negative phenotype (TNP) defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) to examine whether such inclusion improves the prognostic accuracy of TNM staging for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Women diagnosed with primary invasive ductal breast cancer from January 1, 1991, through December 31, 2008, were identified from a prospective institutional database. Excluded were patients who received neoadjuvant therapy, those whose staging information was incomplete, or those whose tumor lacked ER, PR, and HER2 data. Breast cancers were categorized by TNM stage and by the presence or absence of TNP. MAIN OUTCOMES AND MEASURES: Overall survival at 5 years. RESULTS: Database review identified 1842 consecutive eligible patients with breast cancer. When patients were stratified by TNM stage, overall survival curves for those with TNP breast cancer matched those for patients whose non-TNP breast cancer was 1 TNM stage higher. Multivariable analysis showed that TNP status was a powerful prognostic variable, and the likelihood ratio test revealed that the prognostic accuracy of the TNM staging system that incorporated TNP was superior to the current TNM staging system (P < .001). A TNM staging system that incorporated TNP reduced early-stage compression by 15%. CONCLUSIONS AND RELEVANCE: The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging.

AB - IMPORTANCE: Nonanatomic factors, such as histologic grade and biomarkers, can guide breast cancer management but are not included in the current TNM staging system. OBJECTIVE: To use as an example the triple-negative phenotype (TNP) defined by the absence of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor 2 (HER2) to examine whether such inclusion improves the prognostic accuracy of TNM staging for breast cancer. DESIGN, SETTING, AND PARTICIPANTS: Women diagnosed with primary invasive ductal breast cancer from January 1, 1991, through December 31, 2008, were identified from a prospective institutional database. Excluded were patients who received neoadjuvant therapy, those whose staging information was incomplete, or those whose tumor lacked ER, PR, and HER2 data. Breast cancers were categorized by TNM stage and by the presence or absence of TNP. MAIN OUTCOMES AND MEASURES: Overall survival at 5 years. RESULTS: Database review identified 1842 consecutive eligible patients with breast cancer. When patients were stratified by TNM stage, overall survival curves for those with TNP breast cancer matched those for patients whose non-TNP breast cancer was 1 TNM stage higher. Multivariable analysis showed that TNP status was a powerful prognostic variable, and the likelihood ratio test revealed that the prognostic accuracy of the TNM staging system that incorporated TNP was superior to the current TNM staging system (P < .001). A TNM staging system that incorporated TNP reduced early-stage compression by 15%. CONCLUSIONS AND RELEVANCE: The internationally recognized and easily reproducible examination of ER, PR, and HER2 status exemplifies how nonanatomic factors can improve the prognostic accuracy of breast cancer staging.

UR - http://www.scopus.com/inward/record.url?scp=84894583221&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894583221&partnerID=8YFLogxK

U2 - 10.1001/jamasurg.2013.3181

DO - 10.1001/jamasurg.2013.3181

M3 - Article

VL - 149

SP - 125

EP - 129

JO - JAMA Surgery

JF - JAMA Surgery

SN - 2168-6254

IS - 2

ER -